|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Ubiquitin-conjugating enzyme E2S (UBE2S) is important for the development and progression of several types of cancer.
|
31814735 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Moreover, we demonstrated that UBE2S plays a critical role in determining the malignancy properties of human colorectal cancer (CRC) cells in vitro and in vivo.
|
29674637 |
2018 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Ubiquitin-conjugating enzyme E2S (UBE2S) plays pivotal roles in the progression of human cancers.
|
29928880 |
2018 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Targeting the E2-EPF pathway may have potential clinical applications for the treatment of cervical cancer.
|
22895574 |
2012 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
E2-EPF ubiquitin carrier protein (UCP) has been shown to be highly expressed in common human cancers and target von Hippel-Lindau (VHL) for proteosomal degradation in cells, thereby stabilizing hypoxia-inducible factor (HIF)-1alpha.
|
18780286 |
2008 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We identified the ubiquitin-conjugating enzyme E2-EPF mRNA as differentially expressed in breast tumors relative to normal tissues and performed studies to elucidate its putative role in cancer.
|
17710163 |
2007 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
E2-EPF ubiquitin carrier protein (UCP) catalyzes ubiquitination of itself and von Hippel-Lindau protein (pVHL) for degradation and associates with tumor growth and metastasis.
|
30903204 |
2019 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Immunohistochemistry confirmed that the protein level of UBE2S increased in tissue microarrays (TMAs) and was associated with lymph nodes metastasis and distant metastasis.
|
31814735 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Ubiquitin-conjugating enzyme E2S (UBE2S) is important for the development and progression of several types of cancer.
|
31814735 |
2019 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, Gene set enrichment analysis (GSEA) revealed that high UBE2S expression in HCC patients is associated with increased expression in gene sets associated with decreased survival, increased metastasis and increased recurrence.
|
30041036 |
2018 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Moreover, we demonstrated that UBE2S plays a critical role in determining the malignancy properties of human colorectal cancer (CRC) cells in vitro and in vivo.
|
29674637 |
2018 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Targeting the E2-EPF pathway may have potential clinical applications for the treatment of cervical cancer.
|
22895574 |
2012 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We identified the ubiquitin-conjugating enzyme E2-EPF mRNA as differentially expressed in breast tumors relative to normal tissues and performed studies to elucidate its putative role in cancer.
|
17710163 |
2007 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis.
|
16819549 |
2006 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Colony formation, scratch wound-healing and tumor growth assays were conducted to examine the effect of UBE2S on PDAC cells.
|
31814735 |
2019 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Stabilization of E2-EPF UCP protein is implicated in hepatitis B virus-associated hepatocellular carcinoma progression.
|
30903204 |
2019 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Mechanistically, UBE2S enhanced the ubiquitination of p53 protein to facilitate its degradation in HCC cells.
|
29928880 |
2018 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, UBE2S may hold prognostic value in the treatment of HCC.
|
30041036 |
2018 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Because E2-EPF protein levels were elevated during the G(2)/M phase of the cell cycle and because E2-EPF mRNA in tumor specimens was frequently coexpressed with genes involved in cell cycle control, spindle assembly, and mitotic surveillance, the possibility that E2-EPF might have a function in the cellular response to agents that induce a G(2) checkpoint or an M checkpoint was investigated.
|
17710163 |
2007 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis.
|
16819549 |
2006 |
|
Esophageal Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Activation of NF-kappa B, increase of E2-EPF ubiquitin carrier protein and subsequent epithelial-mesenchymal transition might be the underlying mechanisms of the more aggressive tumor growth in IL-1 beta-positive esophageal cancer.
|
21912958 |
2012 |
|
Esophageal carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Activation of NF-kappa B, increase of E2-EPF ubiquitin carrier protein and subsequent epithelial-mesenchymal transition might be the underlying mechanisms of the more aggressive tumor growth in IL-1 beta-positive esophageal cancer.
|
21912958 |
2012 |
|
Malignant neoplasm of esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
Activation of NF-kappa B, increase of E2-EPF ubiquitin carrier protein and subsequent epithelial-mesenchymal transition might be the underlying mechanisms of the more aggressive tumor growth in IL-1 beta-positive esophageal cancer.
|
21912958 |
2012 |
|
Esophageal Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the role of E2-EPF ubiquitin carrier protein (UCP) in esophageal cancer remains relatively unstudied.
|
19083192 |
2009 |
|
Esophageal carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
However, the role of E2-EPF ubiquitin carrier protein (UCP) in esophageal cancer remains relatively unstudied.
|
19083192 |
2009 |